Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Dementia01:30

Dementia

672
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
672
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Amyloid Fibrils03:03

Amyloid Fibrils

12.8K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.8K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.9K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts.

bioRxiv : the preprint server for biology·2026
Same author

Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Outcomes of dyadic recruitment in the promoting re-engagement in meaningful activity (PRIMA) trial.

Contemporary clinical trials·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease.

Brain communications·2026

Related Experiment Video

Updated: Mar 23, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K

Alzheimer Disease.

Liana G Apostolova

    Continuum (Minneapolis, Minn.)
    |April 5, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Recent advances in Alzheimer disease (AD) diagnosis and treatment include visualizing amyloid pathology using positron emission tomography (PET) scans. New criteria incorporate biomarkers, improving clinical diagnosis and future therapeutic strategies for AD.

    More Related Videos

    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
    09:45

    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

    Published on: March 22, 2016

    10.9K
    Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
    06:02

    Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

    Published on: July 26, 2011

    37.6K

    Related Experiment Videos

    Last Updated: Mar 23, 2026

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
    05:17

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

    Published on: April 18, 2025

    1.1K
    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
    09:45

    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

    Published on: March 22, 2016

    10.9K
    Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
    06:02

    Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

    Published on: July 26, 2011

    37.6K

    Area of Science:

    • Neurology
    • Biomarkers
    • Neuroimaging

    Background:

    • Alzheimer disease (AD) diagnosis and treatment have seen significant recent advancements.
    • Understanding of AD's clinical onset, progression, and risk factors has improved.

    Purpose of the Study:

    • To discuss recent advances in the diagnosis and treatment of Alzheimer disease (AD).
    • To highlight key developments in genetics, neuroimaging, and clinical staging of AD.

    Main Methods:

    • Review of recent literature on Alzheimer disease (AD) diagnosis and treatment.
    • Focus on advances in neuroimaging, particularly amyloid positron emission tomography (PET).
    • Analysis of revised diagnostic criteria incorporating biomarkers.

    Main Results:

    • Significant progress in visualizing amyloid pathology in living individuals using amyloid PET.
    • Revised diagnostic criteria for AD dementia now support the use of biomarkers.
    • Development of guidelines for responsible amyloid PET imaging use and exploration of its implications.

    Conclusions:

    • Improved understanding of AD's multifaceted aspects impacts diagnostic approaches.
    • Advances in diagnosis and understanding of risk factors pave the way for future therapeutic interventions.
    • Biomarker integration and advanced neuroimaging are transforming AD management.